In a report released on January 27, Naz Rahman from Maxim Group reiterated a Buy rating on Silexion Therapeutics (SLXN – Research Report), with ...
Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic ...
Stocktwits on MSN8d
TRIB, SLXN, STSS: Why Retail Chatter On 3 Nano-Cap Healthcare Stocks Exploded Over 6000%Three nano-cap healthcare stocks drew massive attention from retail investors on Stocktwits Tuesday, though not all for ...
New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...
It expects to announce details of its expanded development plan shortly. Price Action: SLXN stock is up 130.2% at $1.33 at last check Tuesday.
In a remarkable display of market confidence, Moringa Acquisition Corp (MACA) stock has reached an all-time high, touching a price level of $13.56. This peak represents a... ByInvesting.com ...
In a challenging year for Moringa Acquisition Corp (SLXN), the company's stock has plummeted to a 52-week low, trading at $0.79, with a market capitalization of just $1.29 million. InvestingPro ...
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech ...
Get the Real Story Behind Every Major Earnings Report Silexion Therapeutics Corp. SLXN revealed new preclinical results demonstrating the synergistic efficacy of its SIL-204, in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback